scholarly journals CHANGES IN IMMUNITY PARAMETERS DURING RADIОTHERAPY FOR HEAD AND NECK CANCER DEPENDING ON THE METHOD OF RADIATION TOXICITY PREVENTION

2021 ◽  
Vol 19 (2) ◽  
pp. 212-218
Author(s):  
L. B. Parkhomenko ◽  
Keyword(s):  
Head And Neck Cancer ◽  
Acute Toxicity ◽  
Head And Neck ◽  
Inflammatory Cytokines ◽  
Neck Cancer ◽  
Randomized Study ◽  
Comparative Assessment ◽  
Control Group ◽  
Radiation Toxicity ◽  
Pro Inflammatory Cytokines

Background: The use of magnetolaser and local hypoxia during radiotherapy for head and neck cancer leads to decrease in acute toxicity. Purpose: To reduce the severity of acute toxicity in patients with head and neck cancer using the developed methods of prevention. Material and Methods: A prospective randomized study included 120 patients with head and neck cancer. A comparative assessment of the effectiveness of the three developed methods of prevention was carried out in comparison with traditional prevention. Results: The use of magnetolaser, local hypoxia and their combination led to decrease in the level of pro-inflammatory cytokines and increase in anti-inflammatory cytokines as compared with the control group. This corresponded to a lesser degree of acute toxicity in the main groups. Conclusions: The use of magnetolaser and/or hypoxia reduces acute toxicity, which is confirmed by changes in immunity parameters.

scholarly journals Acute Toxicity and Preliminary Clinical Outcomes of Concurrent Radiation Therapy and Weekly Docetaxel and Daily Cisplatin for Head and Neck Cancer

2005 ◽  
Vol 35 (11) ◽  
pp. 639-644 ◽  
Author(s):  
Yoshizumi Kitamoto ◽  
Tetsuo Akimoto ◽  
Hitoshi Ishikawa ◽  
Tetsuo Nonaka ◽  
Hiroyuki Katoh ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Head And Neck Cancer ◽  
Acute Toxicity ◽  
Head And Neck ◽  
Clinical Outcomes ◽  
Neck Cancer ◽  
Weekly Docetaxel

DOES AGE MATTER FOR RADICAL CHEMORADIATION IN HEAD AND NECK CANCER: A POST-HOC ANALYSIS OF A RANDOMIZED STUDY

2019 ◽  
Vol 10 (6) ◽  
pp. S51-S52
Author(s):  
V.M. Noronha ◽  
V. Patil ◽  
A. Joshi ◽  
N. Menon ◽  
J. Agarwal ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Randomized Study ◽  
Post Hoc Analysis ◽  
Post Hoc

scholarly journals Case-control study of oral disease indexes in individuals with head and neck cancer after antineoplastic therapy

2018 ◽  
Vol 16 (3) ◽  
Author(s):  
Reyna Aguilar Quispe ◽  
Adrielle Lindolpho Cremonesi ◽  
Jeanne Kelly Gonçalves ◽  
Cassia Maria Fischer Rubira ◽  
Paulo Sérgio da Silva Santos
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Permanent Teeth ◽  
Control Group ◽  
Study Group ◽  
Periodontal Index ◽  
Community Periodontal Index ◽  
History Of ◽  
Antineoplastic Treatment

ABSTRACT Objective To evaluate the oral health of patients with head and neck cancer after antineoplastic treatment, and to compare them with patients with no history of cancer. Methods A total of 75 patients, divided into Study Group, composed of individuals after antineoplastic treatment (n=30), and Control Group, with individuals with no history of cancer (n=45), aged 37 to 79 years. The oral health status was evaluated through the index of decayed, missing or filled permanent teeth (DMFT), community periodontal index and evaluation of the use and need of prosthesis. All of these items were evaluated according to the criteria recommended by the World Health Organization. The statistical analysis was descriptive and used the Pearson’s χ2 test. Results The community periodontal index was higher in the Study Group when compared to the Control Group (p<0.0001). The need for an upper (p<0.001) and lower (p<0.0001) prostheses was higher in the Study Group. Also, the use of upper prosthesis was higher in the Study Group (p<0.002). The missing or filled permanent teeth index between the two groups (p>0.0506) and the use of lower prosthesis (p>0.214) did not present a relevant statistical difference. Conclusion Periodontal disease and edentulism are the most significant changes in individuals who received antineoplastic therapy for head and neck cancer as well as greater need for oral rehabilitation.

scholarly journals Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer

1999 ◽  
Vol 10 (6) ◽  
pp. 693-700 ◽  
Author(s):  
A.S.T. Planting ◽  
G. Catimel ◽  
P.H.M. de Mulder ◽  
A. de Graeff ◽  
F. Höppener ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Randomized Study ◽  
Advanced Head ◽  
Short Course ◽  
Weekly Cisplatin

scholarly journals Quantitative Assessment of Serum Magnesium Levels in Head and Neck Cancer: A Tertiary Hospital Based Case Control Study

2021 ◽  
pp. 249-257
Author(s):  
Surender Kumar ◽  
Neha Salaria ◽  
Deepak Verma ◽  
Uma Garg ◽  
Monika Verma
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Case Control Study ◽  
Serum Magnesium ◽  
Tertiary Care ◽  
Case Control ◽  
Control Group ◽  
Control Study

Background- Head and neck squamous cell carcinomas(HNSCC) are one of the most widespread malignancies worldwide. Trace elements such as magnesium are essential at cellular level, and it has been suggested that magnesium plays a role in carcinogenesis. Methods- A hospital based case control study was conducted in a tertiary care medical college with an aim to determine the levels of serum magnesium in patients with head and neck cancer and to  compare  the  levels  of  serum  magnesium  of head and neck cancer patients   with healthy matched control  group  and  derive significance if any. Results- HNSCC was mainly found in males of age group 46 to 55 years. The mean serum Mg value of head and neck cancer patients was 0.71± 0.18 mmol/l while that seen in controls was 0.85± 0.09 mmol/l which was significantly lower(p<0.001). Average serum magnesium levels in stages I, II, III and IV were 0.85, 0.849, 0.682 and 0.554 mmol/l respectively, and a statistically significant association was determined between the two. Conclusion- As the stage of cancer progressed, average magnesium levels decreased congruently, hence establishing that magnesium levels were undeniably correlated to onset as well as progression of HNC. These evidences could be utilized to identify role of magnesium asa potential prognostic biomarker to assess progression of disease or clinical response to various modes of therapy in head and neck cancer patients.

OC-0375: Hypoxia dose-escalation with chemoradiation in head and neck cancer: planned interim analysis of a randomized study

2014 ◽  
Vol 111 ◽  
pp. S145
Author(s):  
S. Welz ◽  
C. Pfannenberg ◽  
M. Reimold ◽  
G. Reischl ◽  
P.S. Mauz ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Dose Escalation ◽  
Interim Analysis ◽  
Randomized Study

scholarly journals Radiation-Related Superficial Oral Mucoceles: an Under-Recognized Acute Toxicity in Head and Neck Cancer Patients

2018 ◽  
Vol 126 (3) ◽  
pp. e154
Author(s):  
Ana Carolina Prado Ribeiro ◽  
Alan Roger Santos-Silva ◽  
Karina Morais-Faria ◽  
Wagner Gomes Da Silva ◽  
Thaís Bianca Brandão
Keyword(s):  
Head And Neck Cancer ◽  
Acute Toxicity ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer

scholarly journals Antitumor Efficacy of Liposome-Encapsulated NVP-BEZ235 Combined with Irreversible Electroporation for Head and Neck Cancer

Molecules ◽  
2019 ◽  
Vol 24 (19) ◽  
pp. 3560
Author(s):  
Li Tian ◽  
Lucas Wang ◽  
Yang Qiao ◽  
Linfeng Lu ◽  
Patrick Lee ◽  
...  
Keyword(s):  
Growth Rate ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Tumor Cells ◽  
Neck Cancer ◽  
Irreversible Electroporation ◽  
Antitumor Efficacy ◽  
Treatment Center ◽  
Control Group ◽  
Tumor Mass

Irreversible electroporation (IRE) kills tumor cells by the delivery of short pulses of strong electric fields. However, the field strength decreases with distance from the treatment center. When IRE cannot eradicate the entire tumor mass, the surviving tumor cells can regrow. NVP-BEZ235 is a dual PI3K/mTOR inhibitor that has been administered orally in clinical trials. However, its hydrophobicity and poor water solubility make NVP-BEZ235 difficult to deliver to target areas. To improve its pharmacokinetics and therapeutic efficacy, we have encapsulated NVP-BEZ235 in a liposome (termed as L-BEZ). Our current study focuses on the long-term antitumor efficacy of IRE and intratumoral injection of L-BEZ in HN5 head and neck cancer xenografts in nude mice. We compared in vitro efficacy, as well as the effect on tumor size and growth rate in vivo, between IRE alone, IRE + oral BEZ, and IRE + L-BEZ over the course of two months. All animals in the control group were sacrificed by day 36, due to excess tumor burden. Tumors treated with IRE alone grew faster and larger than those in the control group. IRE + oral BEZ suppressed tumor growth, but the growth rate increased to that of the controls toward the end of 21 days. Only IRE + L-BEZ eradicated the tumor masses, with no palpable or extractable tumor mass observed after two months. The combination of IRE and L-BEZ could effectively eradicate tumors and prevent recurrence.

Sign in / Sign up

Export Citation Format

Share Document